C12N 2770/32351
Methods of production or purification of viral material
C12N2770/32351 (Methods of production or purification of viral material) appears on 27 US grants and 35 published applications in this corpus.
Search patents in C12N- Granted patents
- 27
- Published applications
- 35
- Assignees
- 37
- Inventors
- 109
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 1 |
| 2014 | 1 | 0 |
| 2015 | 2 | 5 |
| 2016 | 1 | 3 |
| 2017 | 1 | 2 |
| 2018 | 4 | 5 |
| 2019 | 2 | 2 |
| 2020 | 4 | 3 |
| 2021 | 0 | 2 |
| 2022 | 2 | 3 |
| 2023 | 2 | 0 |
| 2024 | 0 | 2 |
| 2025 | 2 | 0 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Optimized oncolytic viruses and uses thereof13 Jan 2026US 12,521,424 B2Sator Therapeutics
- Optimized oncolytic viruses and uses thereof15 Jul 2025US 12,357,664 B2Sator Therapeutics
- Coxsackievirus A6 strain CVA6-KM-J33 and use thereof4 Feb 2025US 12,215,358 B1Institute of Medical Biology, Cams
- Engineered cells with decreased gene expression resulting in increased viral production23 May 2023US 11,655,471 B2University of Georgia Research Foundation, Inc.
- Recombinant polypeptides derived from FBP1 and FBP2 and uses of the same25 Apr 2023US 11,634,464 B2Chang Gung University
- Method for separating and purifying cvb123 Apr 2026US 2026/0109955 A1Hangzhou Yangshengtang Biopharma Co., Ltd.
- Bivalent inactivated ev71-ca16 vaccine, method for preparing the same, and use thereof12 Mar 2026US 2026/0069673 A1Aim Action Biopharm Co., Ltd
- Encapsulated rna polynucleotides and methods of use11 Apr 2024US 2024/0115636 A1ElevateBio Technologies, Inc.
- Enterovirus purification with cation exchange chromatography8 Feb 2024US 2024/0043813 A1Merck Sharp & Dohme Corp.
- Encapsulated rna polynucleotides and methods of use21 Apr 2022US 2022/0117902 A1
Most cited
By later US patents
- Methods for the prevention of aggregation of viral components6US 10,080,793 B2De Staat Der Nederlanden, Vert.Door De Minister Van Vws, Ministerie Van Volksgezonheid, Welzijn En Sport · 2018
- IPV-DPT vaccine6US 8,753,646 B2Japan Poliomyelitis Research Institute · 2014
- Method of producing a virus vaccine from an African green monkey kidney cell line4US 5,911,998 ADyncorp · 1999
- Cell lines for virus production and methods of use2US 10,137,188 B2The United States of America, as represented by the Secretary, Dept. of Health and Human Services · 2018
- Systems for detection and production of respiratory, herpes and enteric viruses2US 7,435,588 B2Diagnostic Hybrids, Inc. · 2008